Cipla's Profit Soars 49% to Rs 1,571 Crore in Q3 FY25, Beating Estimates

Pharmaceutical giant Cipla reported a stellar performance in Q3 FY25, with its consolidated net profit surging 49% year-on-year to Rs 1,571 crore. The company's revenue from operations grew by 7.10% to Rs 7,072.97 crore, driven by strong growth across all geographies. Cipla's EBITDA margin improved to 28.1%, the highest ever, supported by a healthy product mix and operational efficiencies. The One India Business grew by 10% YoY, while the North America business delivered quarterly revenue of $226 million. Cipla's impressive results exceeded market expectations, showcasing its robust growth strategy and market leadership.
Source: Business Standard